Physician profile
Andrea Richardson
NPI 1023069523
$24,348.81
in general payments reported to CMS, 2019-2025
3 companies · $5,445 in 2025
The $5,445 reported for 2025 was more than what 98% of Cytopathology providers received nationally (typical 2025 total: $55.75).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,011 · 2020: $2,000 · 2022: $5,750 · 2024: $5,143 · 2025: $5,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,587.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Uk Limited | $12,587.50 | 2020-2025 | |
| Daiichi Sankyo INC. | $11,750.00 | 2019-2022 | |
| Roche Diagnostics Corporation | $11.31 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Richardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.